

**AMENDMENTS TO THE CLAIMS**

Claim 1 (currently amended): A process of making a solid pharmaceutical composition comprising moexipril magnesium, said process comprising the step of reacting moexipril or an acid addition salt thereof with an alkaline magnesium compound in the presence of a sufficient amount of solvent so as to convert at least 70% of the moexipril or moexipril acid addition salt to moexipril magnesium.

Claim 2 (previously amended): The process of Claim 1 comprising the steps of:

- i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent and mixing in the liquid state;
- ii) evaporating the solvent to obtain a dried material, and
- iii) further processing the dried material into the solid pharmaceutical composition.

Claim 3 (previously amended): The process of Claim 2 wherein, before the solvent is evaporated, the liquid is filtered to remove unreacted alkaline magnesium compound.

Claim 4 (previously amended): The process of Claim 2 or 3 wherein the solvent is evaporated by spray-drying.

Claim 5 (previously amended): The process of Claim 1 comprising the steps of:

- i) adding the moexipril or acid addition salt thereof and the alkaline magnesium compound to solvent;
- ii) using the resultant solution or suspension to wet granulate with excipients to obtain a wet mass;
- iii) drying the wet mass to obtain a dried mass; and
- iv) further processing the dried mass into the solid pharmaceutical composition.

Claim 6 (previously amended): The process of Claim 1 comprising the steps of:

- i) adding the alkaline magnesium compound to solvent;

- ii) using the resulting solution or suspension to wet granulate a mixture of the moexipril or acid addition salt thereof and one or more excipients to obtain a wet mass;
- iii) drying the wet mass to obtain a dried mass; and
- iv) further processing the dried mass into the solid pharmaceutical composition.

Claim 7 (previously amended): The process of Claim 1 comprising the steps of:

- i) adding the moexipril or acid addition salt thereof to solvent;
- ii) using the resultant solution or suspension to wet granulate a mixture of the alkaline magnesium compound and one or more excipients to obtain wet mass;
- iii) drying the wet mass to obtain a dried mass, and
- iv) further processing the dried mass into the solid pharmaceutical composition.

Claim 8 (previously amended): The process of Claim 1 comprising the steps of:

- i) mixing the moexipril or acid addition salt thereof and alkaline magnesium compound with one or more excipients;
- ii) adding a solvent and mixing to obtain a wet mass;
- iii) drying the wet mass to obtain a dry mass; and
- iv) further processing the dried mass into the solid pharmaceutical composition.

Claim 9 (previously amended): The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

Claim 10 (previously amended): The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

Claim 11 (previously amended): The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

Claim 12 (previously amended): The process of any one of Claims 1, 2, 3, 5, 6, 7, or 8 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is greater than 80%.

Claim 13 (previously amended): The process of Claim 12 wherein the percentage of the moexipril or acid addition salt thereof converted to moexipril magnesium is greater than 90%.

C2 Claim 14 (currently amended): A solid pharmaceutical composition comprising moexipril wherein at least 70% of the moexipril present in the composition is moexipril magnesium.

Claim 15 (previously added): The process of Claim 4 where the solvent is selected from a group of solvents comprising water, an organic solvent, acetone, or combinations thereof.

Claim 16 (previously added): The process of Claim 4 wherein the moexipril or acid addition salt thereof is moexipril hydrochloride.

Claim 17 (previously added): The process of Claim 4 wherein the alkaline magnesium compound is selected from the group of compounds comprising magnesium hydroxide, magnesium oxide, magnesium carbonate, or the magnesium salt of a weak acid.

Claim 18 (previously amended): The process of Claim 4 wherein the percentage of the moexipril or acid addition salt converted to moexipril magnesium is greater than 80%.